Publication Name	World Journal of Clinical Cases
Manuscript ID	28069
Country	United States

Received	2016-06-29 09:26
Peer-Review Started	2016-06-29 17:14
To Make the First Decision	2016-08-04 16:10
Return for Revision	2016-08-05 09:22
Revised	2016-09-19 00:00
Second Decision	2016-10-10 09:33
Accepted by Journal Editor-in-Chief
Accepted by Executive Editor-in-Chief	2016-10-24 14:39
Articles in Press	2016-10-24 14:39
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2016-11-28 19:06
Publish the Manuscript Online	2016-12-07 09:15

ISSN	2307-8960 (online)
Open Access	This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright	© The Author(s) 2016. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Dermatology
Manuscript Type	Case Report
Article Title	Paclitaxel-associated reticulate hyperpigmentation: Report and review of chemotherapy-induced reticulate hyperpigmentation
Manuscript Source	Invited Manuscript
All Author List	Philip R Cohen
Funding Agency and Grant Number
Corresponding Author	Philip R Cohen, MD, Department of Dermatology, University of California San Diego, 10991 Twinleaf Court, San Diego, CA 92131-3643, United States. mitehead@gmail.com
Key Words	Breast; Cancer; Chemotherapy; Hyperpig­mentation; Neoplasm; Reticulate; Tumor; Paclitaxel; Taxol
Core Tip	Chemotherapy-induced reticulate hyper-pigmentation has been described in four men and six women being treated for either a hematologic malignancy or a solid tumor. Associated drugs included cytoxan (with or without idarubicin), paclitaxel, 5-fluorouracil and bleomycin. The skin lesions were usually asymptomatic and appeared as linear macular hyperpigmention that was lacy, net-like, or both on the pati-ent’s back. The hyperpigmentation appeared within 3 d to 18 wk after starting the drug and faded within 2 to 6 mo after stopping the medication. Chemotherapy-induced reticulate hyperpigmentation did not require dose reduction or discontinuation of the associated antineoplastic treatment.
Publish Date	2016-12-07 09:15
Citation	Cohen PR. Paclitaxel-associated reticulate hyperpigmentation: Report and review of chemotherapy-induced reticulate hyperpigmentation. World J Clin Cases 2016; 4(12): 390-400
URL	http://www.wjgnet.com/2307-8960/full/v4/i12/390.htm
DOI	http://dx.doi.org/10.12998/wjcc.v4.i12.390

Full Article (PDF)	WJCC-4-390.pdf
Full Article (Word)	WJCC-4-390.doc
Manuscript File	28069-Review.docx
Answering Reviewers	28069-Answering reviewers.pdf
Audio Core Tip	28069-Audio core tip.mp3
Conflict-of-Interest Disclosure Form	28069-Conflict-of-interest statement.pdf
Copyright License Agreement	28069-Copyright assignment.pdf
Signed Informed Consent Form(s) or Document(s)	Informed_Consent_Statement_20160626003457.pdf
Institutional Review Board Approval Form or Document	28069-Institutional review board statement.pdf
Supplementary Material	Supplementary_Material_20160626005416.JPG
Peer-review Report	28069-Peer-review(s).pdf
Scientific Misconduct Check	28069-Scientific misconduct check.pdf
Scientific Editor Work List	28069-Scientific editor work list.pdf